menu
    • menu
    [{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Candid Therapeutics"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Tadekinig Alpha","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biologics \/ AB2 Bio"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ IMIDomics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ IMIDomics"}]

    Find Immunology Clinical Drug Pipeline Developments & Deals by WuXi Biologics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Candid Therapeutics

                            Deal Size : $925.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Candid Steps up TCE Deal Momentum with $925M WuXi Partnership

                            Details : Under the agreement, Candid will have exclusive global rights to a tri-specific T-cell Engager discovered by the WuXi Biologics platform for treating autoimmune and inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Candid Therapeutics

                            Deal Size : $925.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMB1001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : IMIDomics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune...

                            Details : Under the agreement, WuXi will provide comprehensive CMC development and current cGMP manufacturing services for IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, to treat Immune-Mediated Inflammatory Diseases.

                            Product Name : IMB1001

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 10, 2023

                            Lead Product(s) : IMB1001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : IMIDomics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadekinig Alpha

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : AB2 Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig al...

                            Details : Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH). WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch.

                            Product Name : r-hIL-18BP

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : Tadekinig Alpha

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : AB2 Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth